
Thermo Fisher Scientific TMO
$ 483.94
-0.73%
Annual report 2025
added 02-26-2026
Thermo Fisher Scientific Depreciation & Amortization 2011-2026 | TMO
Annual Depreciation & Amortization Thermo Fisher Scientific
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.05 B | 1.16 B | 1.07 B | 986 M | 831 M | 658 M | 564 M | 2.27 B | 2.03 B | 1.76 B | 1.69 B | 1.68 B | 1 B | 984 M | 864 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.27 B | 564 M | 1.24 B |
Quarterly Depreciation & Amortization Thermo Fisher Scientific
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 227 M | 256 M | 276 M | 291 M | 276 M | 285 M | - | - | 253 M | - | 730 M | - | 250 M | - | 614 M | - | 198 M | - | 467 M | 306 M | 149 M | - | 416 M | 275 M | 133 M | - | 132 M | 130 M | 575 M | - | 1.46 B | 942 M | 465 M | - | 1.28 B | 851 M | 416 M | - | 1.26 B | 836 M | 416 M | - | 1.26 B | 800 M | 366 M | - | 751 M | 500 M | 251 M | - | 729 M | 484 M | 242 M | - | 614 M | 385 M | 184 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.46 B | 130 M | 506 M |
Depreciation & Amortization of other stocks in the Diagnostics research industry
| Issuer | Depreciation & Amortization | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Agilent Technologies
A
|
321 M | $ 113.95 | -0.77 % | $ 34.6 B | ||
|
CareDx, Inc
CDNA
|
15 M | $ 17.3 | -2.92 % | $ 922 M | ||
|
Akumin
AKU
|
98.2 M | - | -17.87 % | $ 25.9 M | ||
|
Burning Rock Biotech Limited
BNR
|
47.8 M | $ 16.4 | 0.61 % | $ 176 M | ||
|
Co-Diagnostics
CODX
|
1.11 M | $ 4.4 | 101.83 % | $ 5.85 M | ||
|
Aspira Women's Health
AWH
|
112 K | - | -6.19 % | $ 10.5 M | ||
|
Accelerate Diagnostics
AXDX
|
1.7 M | - | -61.36 % | $ 2.46 M | ||
|
National Research Corporation
NRC
|
7.62 M | $ 17.24 | -0.52 % | $ 386 M | ||
|
Global Cord Blood Corporation
CO
|
43.3 M | - | - | $ 399 M | ||
|
Charles River Laboratories International
CRL
|
403 M | $ 168.88 | 0.33 % | $ 8.37 B | ||
|
Castle Biosciences
CSTL
|
16 M | $ 24.9 | 0.67 % | $ 692 M | ||
|
Biocept
BIOC
|
1.66 M | - | -13.05 % | $ 7.29 M | ||
|
Biodesix
BDSX
|
5.77 M | $ 15.24 | -0.78 % | $ 1.98 B | ||
|
Danaher Corporation
DHR
|
750 M | $ 191.24 | -0.44 % | $ 136 B | ||
|
DexCom
DXCM
|
252 M | $ 64.09 | 1.39 % | $ 25 B | ||
|
Fulgent Genetics
FLGT
|
24.9 M | $ 16.44 | 0.12 % | $ 497 M | ||
|
QIAGEN N.V.
QGEN
|
194 M | - | - | $ 10.6 B | ||
|
Guardant Health
GH
|
39.7 M | $ 90.19 | 0.59 % | $ 11.3 B | ||
|
Anixa Biosciences
ANIX
|
38.3 K | $ 2.61 | 0.77 % | $ 84.7 K | ||
|
Biomerica
BMRA
|
87 K | $ 2.13 | -2.07 % | $ 4.89 M | ||
|
BioNano Genomics
BNGO
|
9.53 M | $ 1.13 | -1.7 % | $ 6.15 M | ||
|
ICON Public Limited Company
ICLR
|
488 M | $ 108.32 | -1.18 % | $ 8.93 B | ||
|
Interpace Biosciences
IDXG
|
425 K | $ 1.97 | - | $ 8.72 M | ||
|
Illumina
ILMN
|
354 M | $ 127.78 | 0.03 % | $ 20.3 B | ||
|
Check-Cap Ltd.
CHEK
|
161 K | - | - | $ 9.42 M | ||
|
Celcuity
CELC
|
167 K | $ 113.83 | -0.35 % | $ 5.32 B | ||
|
Laboratory Corporation of America Holdings
LH
|
681 M | $ 275.15 | 0.21 % | $ 22.9 B | ||
|
Lantheus Holdings
LNTH
|
70.1 M | $ 76.09 | 0.26 % | $ 5.14 B | ||
|
DermTech
DMTK
|
200 K | - | -11.32 % | $ 2.94 M | ||
|
Medpace Holdings
MEDP
|
27.2 M | $ 497.15 | 0.23 % | $ 14.3 B | ||
|
Chembio Diagnostics
CEMI
|
2.55 M | - | 0.22 % | $ 16.8 M | ||
|
Enzo Biochem
ENZ
|
1.27 M | - | -8.98 % | $ 14.8 K | ||
|
Exact Sciences Corporation
EXAS
|
125 M | - | - | $ 19.8 B | ||
|
Quest Diagnostics Incorporated
DGX
|
570 M | $ 199.79 | 0.37 % | $ 22.2 B | ||
|
Myriad Genetics
MYGN
|
53.7 M | $ 4.7 | 0.64 % | $ 435 M | ||
|
ENDRA Life Sciences
NDRA
|
44 K | $ 4.74 | - | $ 3.73 M | ||
|
NeoGenomics
NEO
|
36.1 M | $ 8.04 | 0.25 % | $ 1.03 B | ||
|
Neogen Corporation
NEOG
|
119 M | $ 9.63 | 0.73 % | $ 2.09 B | ||
|
Natera
NTRA
|
16.7 M | $ 206.6 | 0.84 % | $ 20.3 B | ||
|
Pacific Biosciences of California
PACB
|
13 M | $ 1.38 | -2.82 % | $ 414 M | ||
|
Precipio
PRPO
|
1.24 M | $ 25.98 | - | $ 41.7 M | ||
|
Personalis
PSNL
|
10.9 M | $ 6.38 | -3.04 % | $ 378 M | ||
|
Heska Corporation
HSKA
|
14 M | - | - | $ 1.31 B |